After nuclear negotiations, the Iranian president says the deal could be reached soon


Bloomberg

J & J Shows Optimism With Covid Vaccine Use in Limbo, USA

(Bloomberg)-Johnson & Johnson says regulators will consider whether shots can cause rare blood clots and inspect factories that are key to pharmaceutical companies achieving production goals. We have shown that uncertainty about the Covid-19 vaccine may be alleviated in the coming days. Six women who received the vaccine stopped using the vaccine last week after developing a serious but rare blood clot in the brain. A committee of medical professionals reviewing data on blood clots can vote on Friday as to whether the hold should end. According to Jason McDonald, a spokesman for the US Centers for Disease Control and Prevention, no additional cases of blood clots have been identified since the suspension began. In an interview, J & J Chief Financial Officer Joseph Wolk rose 2.6% in New York at 11:22 am. This shows that investors are expecting vaccines. The European Medicines Agency’s Safety Commission warned Tuesday that there was a link between rare blood clots and vaccines, but said the potential benefits outweigh the risks. The ruling paves the way for European Union countries to decide whether to limit access to shots for patient groups. The Commission recommended adding a warning to Shot’s product information. As of April 15, approximately 7.7 million people in the United States received J & J shots. J & J said Tuesday that it brought $ 100 million in sales to the company in the first quarter. J & J’s shot was previously considered important to the US vaccination program, but the Biden administration said it expects to be supplemented by other vaccines currently available. Lack caused by a pause. In Europe, where the deployment of broader vaccines is slow, access to J & J shots helps stop the spread of viral variants that cover more residents and contribute to higher infection rates. There is a possibility. Wolk said in an interview Tuesday that he would provide an annual forecast of vaccine sales due to uncertainty about the suspension of vaccine use. J & J offers shots on a non-profit basis for less than $ 10 per dose during the pandemic. Play and make sure we respect it, “Walk said. “This is a non-profit structure and will not have a significant impact on earnings.” This week, US regulators said Emergent BioSolutions Inc, which is responsible for manufacturing the underlying drug substance used. The facility may be inspected. On a phone call with investors, Executive Vice Chairman Joaquin Duato was told by US regulators to suspend work at the Baltimore facility on April 16. Approximately 15 million doses of J & J Shot’s key ingredients had to be discarded after a manufacturing error. J & J executives said Tuesday that it was too early to determine how the hurdles would affect the timing of 100 million doses to the US. A year of $ 9.42 to $ 9.57, narrowing the guidance given in January from $ 9.40 to $ 9.60. Wall Street analysts expect an average of $ 9.50 per share, according to data compiled by Bloomberg. First-quarter sales were $ 22.32 billion, above analysts’ average estimate of $ 21.98 billion. The company’s pharmaceuticals division continues to account for more than half of its sales, with first-quarter sales up 10% to $ 12.2 billion. Medical device sales are up 11% to $ 6.58 billion, and device trends are expected to continue to improve. In the Asia-Pacific region, medical devices recovered 70% this quarter, followed by other regions. “Selective surgery still seems a bit soft from a market perspective,” he said. However, consumer sales were $ 3.54 billion, down 2.3% from the previous year. In consumer health, J & J’s sales of commercial products declined due to a comparison with last year’s pantry load, cough, cold and flu season weakness. 1 year ago. Dividends on Tuesday also increased by 5% from $ 1.01 per share to $ 1.06. (Overall update) Visit bloomberg.com for articles like this. Subscribe now to get the most trusted business news sources. © 2021 Bloomberg LP